Deciphera Pharmaceuticals AG

Deciphera is a biopharmaceutical company dedicated to discovering, developing and delivering new, effective medicines to improve the lives of cancer patients. With deep expertise in kinase biology and our proprietary switch-control inhibitor platform, we are developing innovative therapies for unmet medical needs. Our approved drugs include QINLOCK® for the treatment of advanced-stage GIST and romvimza™ (vimseltinib) for the treatment of TGCT. With a promising pipeline and a clear focus on scientific excellence and patient well-being, Deciphera is setting new standards in oncology - for people worldwide.